The lab, which was temporarily shut down for revision, has again resumed operations to serve stem cell banking customers.
The GTP Centre I, which has been initially completed on 11 October 2011, has a processing capacity of up to 3,000 customers per annum.
Recently Human Biostar has also organised an open lab event to explain revisions made in its GTP Centre I’s configuration and operation system according to FDA recommendations.
South Korea-based RL Bio contributes to human health with stem cell research and development in collaboration with the global medical and scientific institutions.